drugset / Trial / NCT02368665

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

NCT02368665

Phase 3 Completed 180 enrolled HK inno.N Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Compare the safety and efficacy of amlodipine besylate and candesartan cilexetil combination therapy on patients of essential hypertension who are not properly controlled by amlodipine besylate monotherapy.

Timeline

Start
2014-12
Primary completion
2015-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Amlodipine Other / unclassified 10 mg Oral
Subject Candesartan cilexetil Unknown 16 mg